Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Research & Development (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Research & Development data on record, last reported at $51.1 million in Q4 2025.

  • For Q4 2025, Research & Development rose 16.08% year-over-year to $51.1 million; the TTM value through Dec 2025 reached $186.2 million, up 32.39%, while the annual FY2025 figure was $186.2 million, 32.39% up from the prior year.
  • Research & Development reached $51.1 million in Q4 2025 per MIRM's latest filing, up from $43.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $51.1 million in Q4 2025 and bottomed at $22.0 million in Q2 2023.
  • Average Research & Development over 5 years is $33.4 million, with a median of $31.4 million recorded in 2022.
  • Peak YoY movement for Research & Development: soared 119.92% in 2021, then tumbled 36.83% in 2022.
  • A 5-year view of Research & Development shows it stood at $27.8 million in 2021, then grew by 11.99% to $31.1 million in 2022, then dropped by 0.55% to $30.9 million in 2023, then soared by 42.32% to $44.0 million in 2024, then grew by 16.08% to $51.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $51.1 million in Q4 2025, $43.0 million in Q3 2025, and $46.1 million in Q2 2025.